NewCardio Inc. (NWCI.OB) Achieves Milestone with First Revenue-Generating Technology Study
NewCardio Inc. develops proprietary software platform technologies for cardiac diagnostic services. The company’s QTinno software suite offers accurate, automated and comprehensive analysis for cardiac safety assessment in drug development. NewCardio today announced it has completed its first revenue generating study, in collaboration with a leading global biopharmaceutical services provider, with which NewCardio previously signed a Master Services Agreement (MSA) for the use of its QTinno software. The QTinno software was installed at one of the service provider’s phase 1 units to conduct and complete a small initial study. NewCardio said the resulting data will provide an initial cardiac safety profile…